Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

NEW HAVEN, Conn., March 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VIOND) today announced financial results for the fourth quarter and year-end of 2007.

The Company reported a net loss of $34.0 million, or $5.05 per share, for the year ended December 31, 2007, compared with a net loss of $25.3 million, or $3.83 per share, for 2006. Weighted-average common shares outstanding for the years ended December 31, 2007 and December 31, 2006 were 6.7 million and 6.6 million, respectively. The net loss increased in 2007 by $8.7 million over the previous year, primarily as a result of non-cash expenses including: (i) $5.1 million of interest expense related to Vion's convertible senior notes and (ii) $2.5 million of higher stock-based compensation expense. In addition, costs associated with clinical, regulatory and pre-commercialization activities for the Company's lead product candidate, Cloretazine(R) (VNP40101M) increased year-over-year.

The Company reported ending the year with $61.1 million in cash and cash equivalents.

Alan Kessman, Chief Executive Officer, commented, "Based on our current operating plan, we are funded through the third quarter of 2009. We continue to make progress on preparing a New Drug Application for our lead anticancer agent Cloretazine(R) (VNP40101M) for filing with the U.S. Food and Drug Administration in 2008."

A net loss of $8.2 million, or $1.18 per share, was reported for the fourth quarter of 2007, compared with a net loss of $6.1 million, or $0.92 per share, for the same period in 2006. Weighted-average common shares outstanding for the three months ended December 31, 2007 and 2006 were 6.9 million and 6.6 million, respectively.

On February 20, 2008, the Co
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History ... to Juliana Hillis and Kaylie O’Connell, students at Stoneham ... an Egg, Everything: America’s First IVF Baby". This project ... National History Day program during a week-long final competition ... Washington, D.C. , The growing popularity of the assisted ...
(Date:7/29/2014)... , July 29, 2014 ... Biopsy System (LBS) zur Erfassung biologischer Daten ... Herzkranzgefäßen entwickelt und patentiert. Das LBS nimmt ... der Koronararterie des Patienten und sucht erhöhte ... hat das Potenzial, die Entdeckung und Entwicklung ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
... , , ... , , Protector RNase Inhibitor ... wide known spectrum of,RNases. , Does not interfere with the performance of ... concentration) of,Protector RNase Inhibitor are needed to protect difficult RNA samples. , ...
... , , , , ... , , , , ... Polymerase for hot start PCR, was introduced,in 2000. Based on the feedback from many customers,FastStart Taq ... , , , Even the most ...
... , , , ... Increase Power and, Sensitivity in cDNA Synthesis with the new ... , , , With the new recombinant ... high sensitivity in one- or two-step RT-PCR , Obtain full-length cDNA transcripts ...
Cached Biology Technology:Protector RNase Inhibitor Enhance the Protection of,RNA against Degradation 2Challenge the Performance of Your Hot-Start PCRs,with FastStart Taq DNA Polymerase and,the Novel FastStart High Fidelity PCR System 2Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
(Date:7/28/2014)... the Earth that are high priorities for conservation in ... vulnerable, as it has the lowest fraction of its ... in ,refugia, areas of biological diversity that support ... during times of great environmental change. The refugia that ... Scotland. , The biggest refugia are in the ...
(Date:7/28/2014)... that 73 percent of adult survivors of childhood cancer ... and related health problems by failing to follow a ... of the journal Cancer . , Almost 32 ... in the study had metabolic syndrome, an umbrella term ... obesity, elevated triglyceride and other abnormalities that often occur ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... of 35 headwater basins in the United States and Canada ... rates was less than expected in many locations, suggesting that ... change. The study was just published in a special ... Long-Term Ecological Research (LTER) network of 26 sites around the ...
... by UCLA life scientists could lead to predictions of which ... Droughts are worsening around the world, posing a great ... UCLA professor of ecology and evolutionary biology and senior author ... century how to predict which species are most vulnerable. ...
... the University of Notre Dame,s Eck Institute for Global ... identification of malaria drug resistance, an effort that will ... this devastating disease. The new discovery is described in ... of the journal Science . The team of ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Which plants will survive droughts, climate change? 2Which plants will survive droughts, climate change? 3Which plants will survive droughts, climate change? 4Which plants will survive droughts, climate change? 5Notre Dame researchers using novel method to combat malaria drug resistance 2Notre Dame researchers using novel method to combat malaria drug resistance 3
Request Info...
... is able to accept cell lines produced according ... cell lines must be accompanied by a certificate ... with the requirements of cGMP and that they ... or fungi. What are the benefits of the ...
Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
... T7Select Packaging Extracts are optimized for maximum ... insert. The high efficiency extracts (> 109 ... to produce a library containing at least ... arms. The extracts are made from a ...
Biology Products: